Patents by Inventor Kevin Allen D'Amour
Kevin Allen D'Amour has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11904001Abstract: Disclosed herein are universal donor stem cells and cells derived therefrom and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming allogeneic immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor cells disclosed herein are pancreatic endoderm cells that do not express one or more MHC-Class I cell-surface proteins and whose expression of at least one NK activating ligand is disrupted or inhibited.Type: GrantFiled: May 3, 2019Date of Patent: February 20, 2024Assignee: ViaCyte, Inc.Inventors: Anindita Bhoumik, Alan D. Agulnick, Kevin Allen D'Amour
-
Patent number: 11746323Abstract: Disclosed herein are cell cultures comprising PDX1-positive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified PDX1-positive endoderm cells as well as methods for enriching, isolating and purifying PDX1-positive endoderm cells from other cell types. Methods of identifying differentiation factors capable of promoting the differentiation of endoderm cells, such as PDX1-positive foregut endoderm cells and PDX1-negative definitive endoderm cells, are also disclosed.Type: GrantFiled: September 25, 2019Date of Patent: September 5, 2023Assignee: ViaCyte, Inc.Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Susan Eliazer, Emmanuel E. Baetge
-
Publication number: 20230233739Abstract: Disclosed are cell encapsulation devices and methods for transplanting cells, such as pancreatic endoderm cells, into a host. In some examples, a cell encapsulation can comprise a lumen configured to receive cells therein, a cell-excluding membrane, where the lumen is internal to the cell-excluding membrane, and a non-woven fabric layer external to the cell-excluding membrane, where the non-woven fabric layer and the cell-excluding membrane comprise perforations. The device can further comprise a woven mesh external to the non-woven fabric layer, where the non-woven fabric layer provides protection to the cell-excluding membrane from direct contact with the woven mesh.Type: ApplicationFiled: March 2, 2023Publication date: July 27, 2023Applicant: ViaCyte, Inc.Inventors: Kevin Allen D'Amour, Evert Kroon, Michael Scott, Laura Martinson, Craig McGreevy
-
Patent number: 11667889Abstract: This disclosure relates to compositions comprising human preprimitive streak cells and/or human mesendoderm cells as well as methods for their production. Additionally, disclosed herein are methods of identifying factors useful in the further differentiation of preprimitive streak and mesendoderm cell types.Type: GrantFiled: December 17, 2019Date of Patent: June 6, 2023Assignee: ViaCyte, Inc.Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Susan Eliazer, Evert Kroon, Emmanuel E. Baetge
-
Patent number: 11623023Abstract: Disclosed are devices and methods for transplanting cells, such as pancreatic endoderm cells, into a host. The devices include a non-woven fabric external to a cell-excluding membrane, and the non-woven fabric and/or cell-excluding membrane can be perforated. Treatment of the host with immunosuppressive reagents, required to inhibit allograft rejection due to perforations in the cell delivery device, does not compromise maturation or function of transplanted pancreatic endoderm cells.Type: GrantFiled: November 10, 2016Date of Patent: April 11, 2023Assignee: ViaCyte, Inc.Inventors: Kevin Allen D'Amour, Evert Kroon, Michael Scott, Laura Martinson, Craig McGreevy
-
Publication number: 20230040286Abstract: Disclosed herein are cell cultures comprising dorsal and/or ventral PDX1-positive foregut endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified dorsal and/or ventral PDX1-positive foregut endoderm cells as well as methods for enriching, isolating and purifying dorsal and/or ventral PDX1-positive foregut endoderm cells from other cell types. Methods of identifying differentiation factors capable of promoting the differentiation of dorsal and/or ventral PDX1-positive foregut endoderm cells, are also disclosed.Type: ApplicationFiled: July 25, 2022Publication date: February 9, 2023Applicant: ViaCyte, Inc.Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Susan Eliazer, Emmanuel E. Baetge
-
Patent number: 11446335Abstract: A human immature endocrine cell population and methods for making an immature endocrine cell population are provided. Specifically, immature beta cells and methods for production of immature beta cells are described. Immature beta cells co-express INS and NKX6.1 and are uni-potent and thereby develop into mature beta cells when implanted in vivo. The mature beta cells in vivo are capable of producing insulin in response to glucose stimulation.Type: GrantFiled: June 25, 2019Date of Patent: September 20, 2022Assignee: ViaCyte, Inc.Inventors: Alan D. Agulnick, Kevin Allen D'Amour
-
Patent number: 11427805Abstract: Disclosed herein are cell cultures comprising dorsal and/or ventral PDX1-positive foregut endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified dorsal and/or ventral PDX1-positive foregut endoderm cells as well as methods for enriching, isolating and purifying dorsal and/or ventral PDX1-positive foregut endoderm cells from other cell types. Methods of identifying differentiation factors capable of promoting the differentiation of dorsal and/or ventral PDX1-positive foregut endoderm cells, are also disclosed.Type: GrantFiled: November 26, 2018Date of Patent: August 30, 2022Assignee: ViaCyte, Inc.Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Susan Eliazer, Emmanuel E. Baetge
-
Publication number: 20220056405Abstract: Disclosed herein are cell cultures comprising definitive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified definitive endoderm cells as well as methods for enriching, isolating and purifying definitive endoderm cells from other cell types.Type: ApplicationFiled: November 5, 2021Publication date: February 24, 2022Applicant: ViaCyte, Inc.Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Emmanuel E. Baetge
-
Publication number: 20200248137Abstract: This disclosure relates to compositions comprising human preprimitive streak cells and/or human mesendoderm cells as well as methods for their production. Additionally, disclosed herein are methods of identifying factors useful in the further differentiation of preprimitive streak and mesendoderm cell types.Type: ApplicationFiled: December 17, 2019Publication date: August 6, 2020Applicant: ViaCyte, Inc.Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Susan Eliazer, Evert Kroon, Emmanuel E. Baetge
-
Patent number: 10550367Abstract: This disclosure relates to compositions comprising human preprimitive streak cells and/or human mesendoderm cells as well as methods for their production. Additionally, disclosed herein are methods of identifying factors useful in the further differentiation of preprimitive streak and mesendoderm cell types.Type: GrantFiled: October 2, 2018Date of Patent: February 4, 2020Assignee: ViaCyte, Inc.Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Susan Eliazer, Evert Kroon, Emmanuel E. Baetge
-
Publication number: 20200017824Abstract: Disclosed herein are cell cultures comprising PDX1-positive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified PDX1-positive endoderm cells as well as methods for enriching, isolating and purifying PDX1-positive endoderm cells from other cell types. Methods of identifying differentiation factors capable of promoting the differentiation of endoderm cells, such as PDX1-positive foregut endoderm cells and PDX1-negative definitive endoderm cells, are also disclosed.Type: ApplicationFiled: September 25, 2019Publication date: January 16, 2020Applicant: ViaCyte, Inc.Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Susan Eliazer, Emmanuel E. Baetge
-
Publication number: 20190376028Abstract: Disclosed herein are cell cultures comprising definitive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified definitive endoderm cells as well as methods for enriching, isolating and purifying definitive endoderm cells from other cell types.Type: ApplicationFiled: August 13, 2019Publication date: December 12, 2019Applicant: ViaCyte, Inc.Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Emmanuel E. Baetge
-
Patent number: 10465162Abstract: Disclosed herein are cell cultures comprising PDX1-positive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified PDX1-positive endoderm cells as well as methods for enriching, isolating and purifying PDX1-positive endoderm cells from other cell types. Methods of identifying differentiation factors capable of promoting the differentiation of endoderm cells, such as PDX1-positive foregut endoderm cells and PDX1-negative definitive endoderm cells, are also disclosed.Type: GrantFiled: October 31, 2018Date of Patent: November 5, 2019Assignee: ViaCyte, Inc.Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Susan Eliazer, Emmanuel E. Baetge
-
Publication number: 20190328934Abstract: Disclosed are devices and methods for transplanting cells, such as pancreatic endoderm cells, into a host. The devices include a non-woven fabric external to a cell-excluding membrane, and the non-woven fabric and/or cell-excluding membrane can be perforated. Treatment of the host with immunosuppressive reagents, required to inhibit allograft rejection due to perforations in the cell delivery device, does not compromise maturation or function of transplanted pancreatic endoderm cells.Type: ApplicationFiled: November 10, 2016Publication date: October 31, 2019Applicant: Viacyte, Inc.Inventors: Kevin Allen D'Amour, Evert Kroon, Michael Scott, Laura Martinson, Craig McGreevy
-
Publication number: 20190307810Abstract: A human immature endocrine cell population and methods for making an immature endocrine cell population are provided. Specifically, immature beta cells and methods for production of immature beta cells are described. Immature beta cells co-express INS and NKX6.1 and are uni-potent and thereby develop into mature beta cells when implanted in vivo. The mature beta cells in vivo are capable of producing insulin in response to glucose stimulation.Type: ApplicationFiled: June 25, 2019Publication date: October 10, 2019Applicant: ViaCyte, Inc.Inventors: Alan D. Agulnick, Kevin Allen D'Amour
-
Patent number: 10421942Abstract: Disclosed herein are cell cultures comprising definitive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified definitive endoderm cells as well as methods for enriching, isolating and purifying definitive endoderm cells from other cell types.Type: GrantFiled: February 13, 2017Date of Patent: September 24, 2019Assignee: ViaCyte, Inc.Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Emmanuel E. Baetge
-
Patent number: 10391156Abstract: Disclosed herein are universal donor stem cells and cells derived therefrom and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming allogeneic immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor cells disclosed herein are pancreatic endoderm cells that do not express one or more MHC-Class I cell-surface proteins and whose expression of at least one NK activating ligand is disrupted or inhibited.Type: GrantFiled: July 12, 2017Date of Patent: August 27, 2019Assignee: ViaCyte, Inc.Inventors: Anindita Bhoumik, Alan D. Agulnick, Kevin Allen D'Amour
-
Publication number: 20190255159Abstract: Disclosed herein are universal donor stem cells and cells derived therefrom and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming allogeneic immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor cells disclosed herein are pancreatic endoderm cells that do not express one or more MHC-Class I cell-surface proteins and whose expression of at least one NK activating ligand is disrupted or inhibited.Type: ApplicationFiled: May 3, 2019Publication date: August 22, 2019Applicant: ViaCyte, Inc.Inventors: Anindita Bhoumik, Alan D. Agulnick, Kevin Allen D'Amour
-
Patent number: 10376545Abstract: A human immature endocrine cell population and methods for making an immature endocrine cell population are provided. Specifically, immature beta cells and methods for production of immature beta cells are described. Immature beta cells co-express INS and NKX6.1 and are uni-potent and thereby develop into mature beta cells when implanted in vivo. The mature beta cells in vivo are capable of producing insulin in response to glucose stimulation.Type: GrantFiled: April 3, 2017Date of Patent: August 13, 2019Assignee: ViaCyte, Inc.Inventors: Alan D. Agulnick, Kevin Allen D'Amour